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stability at > 40% [3]. A meta-analysis of CRC patients including 
1,277 MSI-H patients showed that MSI-H cancers were associated 
with a better prognosis than MSS cancers [4]. In addition, MSI-H 
cancers have a lower incidence of lymph-node or systemic metas-
tasis compared to MSS cancers. Furthermore, adjuvant 5-Fluoro-
uracil systemic chemotherapy has been revealed to have no onco-
logic benefits in the treatment of stages II and III colon cancer [5]. 
This study analyzed retrospectively the clinicopathologic fea-
tures and prognoses in patients with stages II and III MSI CRCs 
[6]. Surprisingly, current study showed that stage II MSI-H CRC 
had a significantly unfavorable trend for 3-year disease free sur-
vival compared to MSI-L/MSS CRC, even though the study dem-
onstrated that the clinicopathologic features in MSI-H cancer 
were similar to those reported in other studies. Furthermore, in-
terestingly, the MSI-H phenotype was a significantly independent 
poor prognostic factor in the multivariate analysis. 
A previous study had demonstrated that fluorouracil and leu-
covorin (FL) adjuvant chemotherapy was associated with a good 
prognosis for patients with stage II and stage II MSI colorectal 
cancers [7] while another study, in contrast, reported conflicting 
outcomes [8]. This study included only 20 MSI-H patients, which 
number of patients seems to be too small to evaluate any effect of 
FL adjuvant therapy in stage II MSI-H patients. These observa-
tions indicate that MSI status still remains controversial in terms 
of predicting outcomes and personalized therapy. Although the 
benefit of adjuvant chemotherapy has been well established in pa-
tients with stage III CRC, whether FL adjuvant therapy is effective 
for treating for stage II MSI CRC is still not clear. Therefore, stud-
ies with larger numbers of high-risk stage II patients are necessary 
to accurately evaluate the true benefit of adjuvant therapy. Until 
these issues are addressed, concluding that MSI-H patients with 
stage II cancer do not benefit from FL adjuvant therapy may be 
premature. However, MMR status may be especially useful in the 
identification of patients who have Lynch syndrome and may in-
fluence the decision as to the need for further adjuvant treatment 
of CRC patients.
Colorectal cancer (CRC) is a heterogeneous tumor in terms of 
different types of genetic instabilities and molecular pathogeneses. 
Through a molecular analysis, CRC can be classified into several 
groups based on genomic status (microsatellite instability and 
chromosomal instability) and epigenomic status (CpG island 
methylator phenotype) [1]. These molecular characteristics are 
usually more useful than histopathologic features in not only es-
tablishing the pathogenesis of a particular colon cancer but also 
predicting patient prognosis. A microsatellite instability (MSI) is a 
phenomenon that occurs in a subset of CRC (15%–20%) and 
manifests itself as an expansion or a deletion of a microsatellite re-
peat in the patient’s tumor DNA, when compared to the patient’s 
normal DNA. The DNA mismatch repair (MMR) gene normally 
corrects replicative errors. The DNA MMR system consists of 
several proteins, such as MLH1, MSH2, MSH6, and PMS2, which 
detect and correct these errors. A defective DNA MMR and sub-
sequent MSI result either from a MMR gene germline or somatic 
mutation or from methylation of a MMR promoter gene (usually 
MLH1), resulting in the loss of protein function. 
A MSI is generally due to a defective MMR. A defective MMR is 
found in most of the patients with clinically-diagnosed hereditary 
nonpolyposis colorectal cancer (HNPCC) and in approximately 
13%–20% of those diagnosed with sporadic CRC. MSI-H cancers 
generally show a more favorable prognosis than MSS/MSS-L can-
cers [2]. Cancers with or without instability at < 40% of tested loci 
are defined as MSS and MSI-L cancer, respectively. On the other 
hand, MSI-H cancers defined as high degree of microsatellite in-
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